Sunday, March 17, 2019 9:56:34 PM
Uses
Catechol is used as a photographic developer, a developer for fur dyes, as an intermediate for antioxidants
in rubber and lubricating oils, in polymerization inhibitors, and in pharmaceuticals. (1,3,4)
Sources and Potential Exposure
Catechol may be released into the environment during its manufacture and use. (1)
The major routes of human exposure are consumption of contaminated drinking water and ingestion of
contaminated food. (1)
Catechol occurs naturally in fruits and vegetables. (7)
It has been detected in cigarette smoke. (7)
Assessing Personal Exposure
No information was located regarding the measurement of personal exposure to catechol.
Health Hazard Information
Acute Effects:
Skin contact causes eczematous dermatitis in humans. (1,3-6)
In humans, absorption through the skin results in an illness resembling that induced by phenol, except
convulsions are more pronounced. (1,5,6)
Large doses of catechol can cause depression of the CNS and a prolonged rise of blood pressure in
animals. The rise of blood pressure appears to be due to peripheral vasoconstriction. (1,5,6)
Due to the lack of information regarding the duration of exposure in the above studies, it is not clear
whether these health effects were observed following acute or chronic exposure.
Acute animal tests in rats, mice, guinea pigs, and rabbits have demonstrated catechol to have high acute
toxicity by oral or dermal exposure. (2)
Chronic Effects (Noncancer):
No information is available on the chronic effects of catechol in humans or animals.
EPA has not established a Reference Concentration (RfC) or a Reference Dose (RfD) for catechol.
R
ttps://www.epa.gov/sites/production/files/2016-09/documents/catechol-pyrocatechol.pdf
Pharma has stepped off the deep end or scientific knowledge and doesn't have a leg to stand on.
An informed patient can no longer trust the safety of any medicine approved and prescribed under 20th century protocols.
Precision medicine must be implemented ASAP and environmental protection and remediation is just as important. We are killing the planet and we are killing millions around the world if we continue to ignore science.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM

